Eko Health Inc. (Eko) is an American healthcare technology company that develops medical devices, software, and clinical support AI to aid in the detection of cardiovascular and pulmonary diseases.

History

2013-2017: Founding and Early Innovations

Eko was founded in 2013 by Connor Landgraf, Jason Bellet, and Tyler Crouch. Landgraf was inspired to create Eko after seeing the limitations of traditional stethoscopes during his studies in biomedical engineering at the

University of California, Berkeley The University of California, Berkeley (UC Berkeley, Berkeley, Cal, or California), is a Public university, public Land-grant university, land-grant research university in Berkeley, California, United States. Founded in 1868 and named after t ...

and recruited his classmates Bellet and Crouch to join him. In 2015, Eko received

FDA The United States Food and Drug Administration (FDA or US FDA) is a federal agency of the Department of Health and Human Services. The FDA is responsible for protecting and promoting public health through the control and supervision of food ...

clearance for its first product, CORE, a digital attachment for traditional stethoscopes with a compatible smartphone application. In 2015, CORE was named one of TIME Magazine’s Best Inventions. In 2017, Eko received FDA clearance for the DUO, a combined digital stethoscope

ECG Electrocardiography is the process of producing an electrocardiogram (ECG or EKG), a recording of the heart's electrical activity through repeated cardiac cycles. It is an electrogram of the heart which is a graph of voltage versus time of ...

that could be used without a traditional stethoscope.

2018–2022: AI Development and Clinical Expansion

In 2018, Eko's low ejection fraction screening algorithm, developed with the

Mayo Clinic Mayo Clinic () is a Nonprofit organization, private American Academic health science centre, academic Medical centers in the United States, medical center focused on integrated health care, healthcare, Mayo Clinic College of Medicine and Science ...

, received a ‘Breakthrough Device’ designation from the FDA. In 2020, Eko announced $65 million in funding, and a collaboration with 3M. Eko raised an additional $30M in funding in 2022, and received FDA clearance for its murmur analysis software.

2023–Present: AI Adoption and Global Expansion

In 2023, Eko received FDA-clearance for the CORE500 digital stethoscope, which combines artificial intelligence (AI) software, high-fidelity audio, full-color display and 3-lead electrocardiogram (ECG). CORE500 offers compatibility with Eko’s Sensora platform, which uses artificial intelligence (AI) in cardiac disease detection. In April 2024, the company received FDA clearance for its low ejection fraction AI algorithm, developed in collaboration with the Mayo Clinic, enabling early detection of heart failure during routine physical exams. In June 2024, Eko secured $41 million in Series D financing, led by ARTIS Ventures, Highland Capital Partners, NTTVC, and Questa Capital, to expand its AI-driven cardiac screening tools internationally. In November 2024, the American Medical Association (AMA) granted a Category III CPT code to Eko's Sensora AI platform.

References

{{reflist 2014 establishments in California American companies established in 2014 Companies based in Oakland, California Medical device manufacturers Medical technology companies of the United States Medical technology companies